{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:28:01Z","timestamp":1775064481774,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:00:00Z","timestamp":1245196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Imatinib is the current standard frontline therapy for chronic myelogenous leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic response (CCyR); however, complete molecular responses are infrequent. The Bcr\u2010Abl fusion creates a unique sequence of amino acids that could constitute a target for immunomodulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>A mixture of heteroclitic and native peptides derived from both b3a2 and b2a2 sequences was used to vaccinate patients with CML in CCyR who were receiving imatinib therapy and who had stable Bcr\u2010Abl transcript levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Ten patients were enrolled, all with b2a2 transcripts (including 2 patients who had coexpression of b2a2 and b3a2). Patients had received imatinib for a median of 62 months. Three of 10 patients achieved 1\u2010log reduction in Bcr\u2010Abl transcript levels, including the 2 patients who had received previous interferon therapy, and 3 other patients achieved a major molecular response. The vaccine was tolerated well, and there were no grade \u22653 adverse events. Vaccination did not affect the leukocyte profiles in peripheral blood except for regulatory T cells, which were down\u2010regulated briefly during the late stage of vaccination in patients who achieved approximately 1\u2010log reduction in Bcr\u2010Abl transcript levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The current data suggested that vaccination\u2010related transient disruption of immune tolerance may contribute to the reduction in Bcr\u2010Abl transcripts. Clinically, this Bcr\u2010Abl peptide vaccine may transiently improve the molecular response in a subset of patients with CML. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24468","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T18:27:29Z","timestamp":1245263249000},"page":"3924-3934","source":"Crossref","is-referenced-by-count":49,"title":["Synthetic tumor\u2010specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease"],"prefix":"10.1002","volume":"115","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bang\u2010Ning","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan N.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Ebarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/300765a0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(86)90450-2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08362.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403664"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.4.1468"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.10.2680.bloodjournal85102680"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1498"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0954"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404858"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)70931-4"},{"key":"e_1_2_6_17_2","first-page":"1324","article-title":"Synthetic peptide analogs derived from bcr\/abl fusion proteins and the induction of heteroclitic human T\u2010cell responses","volume":"90","author":"Pinilla\u2010Ibarz J","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.4049\/jimmunol.161.4.1705","article-title":"Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues","volume":"161","author":"Zugel U","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.9.1553"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.5.3080"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0587-8"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21854"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22092"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2139"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)70043-2"},{"key":"e_1_2_6_28_2","first-page":"1671","article-title":"Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon\u2010alpha","volume":"6","author":"Reuben JM","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"77a","DOI":"10.1182\/blood.V104.11.259.259","article-title":"Vaccination with the PR1 leukemia\u2010associated antigen can induce complete remission in patients with myeloid leukemia [abstract]","volume":"104","author":"Qazilbash MH","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0250"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0844"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni759"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24468","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:25:34Z","timestamp":1760268334000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24468"}},"subtitle":["A Phase 2 Trial"],"short-title":[],"issued":{"date-parts":[[2009,6,17]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1002\/cncr.24468"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24468","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,17]]}}}